21h
Pharmaceutical Technology on MSNAtsena’s ATSN-201 gains FDA fast track status for XLRS treatmentThe Phase I/II LIGHTHOUSE trial is assessing the safety and tolerability of the gene therapy in male subjects.
In this Healio Video Perspective from the ESCRS winter meeting, Harminder S. Dua, MD, PhD, professor of ophthalmology at the University of Nottingham, discusses the implications of Dua’s layer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results